Lv5
1230 积分 2024-12-17 加入
Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA
8天前
已完结
Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC
8天前
已完结
Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling
8天前
已完结
Osimertinib with or without Chemotherapy in EGFR -Mutated Advanced NSCLC
8天前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
8天前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
8天前
已完结
p53: from understanding its structure to advances in therapeutic targeting
9天前
已完结
Osimertinib with/without chemotherapy in patients with persistent ctDNA EGFR mutant (EGFRm) NSCLC at 3 weeks after 1L osimertinib: A randomized phase II study (FLAME study)
10天前
已关闭
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer
10天前
已完结
Osimertinib with/without chemotherapy in patients with persistent ctDNA EGFR mutant (EGFRm) NSCLC at 3 weeks after 1L osimertinib: A randomized phase II study (FLAME study)
17天前
已关闭
皖公网安备34019202002308
